शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
AKUMSNSEAkums Drugs and Pharmaceuticals Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Thu, 13 Nov, 2025 · 17:52 IST

Q2 results, USD 24M Zambia plant investment approved

Emphasis of matterRevenue declinedEBITDA margin compressionResults View source PDFExplain this filing

AKUMS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-2.9%Reaction day
₹439.00
prior close
₹430.00
announcement price
After-mkt
timing
Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.1%-2.8% vs market
Pharmaceuticals peers, median of 157sector+0.0%-2.9% vs sector

On the reaction day the stock moved 2.8 pts less than Nifty Microcap 250 and 2.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-2.3
10m
-2.5
15m
-3.5
30m
-2.8
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-2.9-0.1-2.8+0.0-2.9
Next day
+0.2+0.5-0.3-0.1+0.4
2d
-2.0-0.3-1.7-0.9-1.2
3d
-3.2-0.5-2.7-1.3-1.8
4d
-4.0-0.8-3.2-1.6-2.4
5d
-3.6-2.3-1.3-2.3-1.4
1w
-3.6-2.8-0.8-2.9-0.7
15d
-4.4-4.9+0.4-3.1-1.4
1m
-3.8-4.7+0.9-4.4+0.5
2m
+1.2-7.7+8.9-5.7+6.9
3m
+8.7-7.8+16.5-10.7+19.4
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Akums approved Q2 and H1 FY26 results. Standalone H1 revenue fell to Rs 541.76 crore from Rs 645.62 crore, PAT at Rs 68.33 crore vs Rs 92.24 crore. Consolidated H1 PAT was Rs 107.38 crore vs Rs 127.86 crore. Board approved USD 24 million (about Rs 200 crore) staggered investment in a new Zambia subsidiary for a manufacturing plant serving African markets. Auditors flagged an ongoing income tax search matter and a new Section 158BC notice as emphasis of matter.

Likely market impact

Sharp standalone profit drop and pending tax matter are negatives, but Zambia plant signals Africa expansion plans.